ALVR
Closed
Allovir inc
9.81
+0.15 (+1.55%)
Last Update: 18 Mar 2025 23:00:00
Yesterday: 9.66
Day's Range: 9.55 - 10.32
Send
sign up or login to leave a comment!
When Written:
3.94
Allovir Inc is a clinical-stage biotechnology company based in Cambridge, Massachusetts. It was founded in 2019 and is focused on developing and commercializing allogeneic, off-the-shelf, virus-specific T cell therapies for the treatment of viral diseases and cancers. The company's lead product candidate, Viralym-M, is a multi-virus specific T cell therapy in development for the treatment of six life-threatening viral infections, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Allovir's technology platform is based on the use of T cells that have been genetically modified to express high levels of virus-specific T cell receptors, which enables them to recognize and kill infected cells. The company is backed by top-tier investors, including Fidelity Management & Research Company, SoftBank Vision Fund, and BlackRock.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








